Gladstone scientists have discovered how a protein deficiency may be linked to frontotemporal dementia (FTD)—a form of early-onset dementia that is similar to Alzheimer’s disease.
Scientists at the Gladstone Institutes have discovered that an FDA-approved anti-epileptic drug reverses memory loss and alleviates other Alzheimer’s-related impairments in an animal model of the disease.
Lennart Mucke, MD, who directs neurological research at the Gladstone Institutes, has received the Khalid Iqbal Lifetime Achievement Award for his exceptional contributions to Alzheimer's disease research.
Gladstone scientists participate in an international consortium that uses stem cell technology to tackle Huntington's disease
Scientists at the Gladstone Institutes have transformed skin cells into cells that develop into a neural network.
Scientists at the Gladstone Institutes have determined how specific circuitry in the brain controls not only body movement but also motivation and learning, providing new insight into neurodegenerative disorders such as Parkinson's disease—and psychiatric disorders such as addiction and depression.
Scientists at the Gladstone Institutes have unraveled a process by which depletion of a specific protein in the brain contributes to the memory problems associated with Alzheimer's disease. These findings provide insights into the disease's development and may lead to new therapies that could benefit the millions of people worldwide suffering from Alzheimer's and other devastating neurological disorders.
The Robert J. and Claire Pasarow Foundation will next week present Gladstone Institutes Senior Investigator and President Emeritus Robert W. Mahley, MD, PhD, with its 2012 Award in Cardiovascular Research, bestowing yet another honor upon Gladstone's founding scientist.
Scientists at the Gladstone Institutes have enhanced our understanding of how a protein linked to Alzheimer's disease keeps young brains healthy, but can damage them later in life—suggesting new research avenues for treating this devastating disease.
Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance—the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes. This breakthrough points to a new way to potentially treat or forestall type 2 diabetes, a rapidly growing global health problem.